Skip to main content

Table 4 Costs and QALY estimates for the three scenarios considered in the cost-utility analysis

From: A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients

 

Intervention (N = 600)

Control (N = 663)

p-value

Mean

Sd

Mean

Sd

P

Scenario 1: 3 months

 Difference in yearly patient costs between T3 and T0 (public healthcare perspective, [13] Euros 2015)

−122.63

747.03

−113.29

828.04

0.01

 Difference in yearly patient costs between T3 and T0 (societal perspective, [6] Euros 2015)

−95.17

660.94

−95.82

741.32

0.01

 Difference1 in QALYs between T3 and T0 [39]

0.02

0.10

0.01

0.10

0.86

Scenario 2: 6 months

 Difference in yearly patient costs between T6 and T0 (public healthcare, [13] Euros 2015)

−154.84

846.47

−113.29

828.04

0.01

 Difference in yearly patient costs between T6 and T0 (societal perspective, [6] Euros 2015)

−115.93

741.45

−95.82

741.32

0.01

 Difference in QALY s between T6 and T0 [39]

0.03

0.12

0.01

0.10

0.01

Scenario 3: 9 months

 Difference in yearly patient costs between T9 and T0 (public healthcare perspective, [13] Euros 2015)

−207.04

828.88

−113.29

828.04

0.01

 Difference in yearly patient costs between T9 and T0 (societal perspective [6] Euros 2015)

−158.56

729.97

−96.12

741.37

0.01

 Difference in QALYs between T9 and T0 [39]

0.04

0.11

0.01

0.10

0.01